New drug for multiple sclerosis! Sanofi brain permeability Btk inhibitor sar442168 phase IIB clinical reached the main end point!

February 7, 2020 / BIOON / -- Sanofi recently announced that its research drug sar442168 (original R & D Code: prn2246) for the treatment of recurrent multiple sclerosis (RMS) in phase IIB reached the main end point In this study, sar442168 significantly reduced disease activity associated with multiple sclerosis (MS) as measured by magnetic resonance imaging (MRI) In this study, sar442168 was well tolerated and no new safety findings were found Detailed results of the study will be presented at the upcoming medical conference Btk inhibitors are believed to regulate adaptive (B cell activation) and innate (CNS microglia) immune cells associated with neuroinflammation in the brain and spinal cord Sar442168 is an oral, brain permeable, selective, small molecule Burton tyrosine kinase (Btk) inhibitor In phase I clinical, it shows Btk binding and CSF exposure The differentiation features of sar442168 (original R & D Code: prn2246) sar442168 is authorized by principia biopharma, and Sanofi has the global right to develop and commercialize the drug The company plans to launch four phase III clinical trials to investigate the effect of sar442168 on MS recurrence rate, disability progression and potential central nervous system damage Phase III trials to treat recurrent and progressive multiple sclerosis are scheduled to start in the middle of this year In the United States and Europe, about 1.2 million people have been diagnosed with MS, an unpredictable chronic disease that attacks the central nervous system Despite the current treatment, many MS patients will continue to experience disability accumulation, and a quarter of MS patients suffer from progressive diseases, with limited or no choice of treatment The global MS treatment market is more than 20 billion euros per year "The vast majority of multiple sclerosis patients experience disability in the course of disease," said John Reed, director of global research and development of sar442168 (prn2246), which can act on both peripheral and central nervous system Sanofi We believe that our Btk inhibitor has the potential to change the treatment of MS This small molecule has the potential to become the first multiple sclerosis therapy targeting B cells The drug not only suppresses the peripheral immune system, but also penetrates the blood-brain barrier, suppresses the immune cells migrating to the brain, and regulates the microglia in the brain related to the progress of multiple sclerosis We are encouraged by these clinical results and look forward to the rapid advancement of this Btk inhibitor into key phase III clinical trials " Source of the original text: Sanofi brain penetrant Btk initiator meets primary endpoint of phase 2 trial in relapsing multiple scissors